| Market Capitalization (Millions $) |
2,016 |
| Shares
Outstanding (Millions) |
63 |
| Employees |
124 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-242 |
| Cash Flow (TTM) (Millions $) |
-72 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Kodiak Sciences Inc. is a biopharmaceutical company that focuses on the development of novel therapies for the treatment of retinal diseases. The company's main area of expertise is in ocular medicine, particularly in targeting and treating chronic conditions that affect the retina.
Kodiak Sciences has developed a proprietary platform technology called the Antibody Biopolymer Conjugate (ABC) platform, which allows for the design and development of potent and durable medicines. By combining the benefits of biologics with the advantages of small molecules, the company aims to deliver innovative therapies that can significantly improve patient outcomes.
One of Kodiak Sciences' most promising drug candidates is KSI-301, a potential treatment for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). KSI-301 has shown promising results in clinical trials, demonstrating its potential to provide improved efficacy and longer duration of action compared to current standard-of-care therapies.
Overall, Kodiak Sciences Inc. is a research-driven biopharmaceutical company that is dedicated to developing transformative treatments for retinal diseases, ultimately aiming to improve the lives of patients suffering from severe and debilitating eye conditions.
Company Address: 1250 Page Mill Road Palo Alto 94304 CA
Company Phone Number: 281-0850 Stock Exchange / Ticker: NASDAQ KOD
|
7.38%